Erlotinib 183321-74-6
1 Inquiries
183321-74-6
Pharmaceutical Grade
99%
shenzhen
Flying
1kg
2025-11-15
vitamin
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceChEBI: A quinazoline compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.
Solid
Erlotinib is a quinazoline compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions. It has a role as an antineoplastic agent, a protein kinase inhibitor and an epidermal growth factor receptor antagonist. It is a member of quinazolines, a terminal acetylenic compound, an aromatic ether and a secondary amino compound.|Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.|Erlotinib is a Kinase Inhibitor. The mechanism of action of erlotinib is as a Protein Kinase Inhibitor.|Erlotinib is a tyrosine kinase receptor inhibitor that is used in the therapy of advanced or metastatic pancreatic or non-small cell lung cancer. Erlotinib therapy is associated with transient elevations in serum aminotransferase levels during therapy and rare instances of clinically apparent acute liver injury.|Erlotinib is a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.|A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.Basic Info-
Product Name:
Erlotinib
Other Name:4-Quinazolinamine,N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-;N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine;OSI 744;Erlotinib;NSC 718781;R 1415;4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
CAS No.:183321-74-6
Molecular Formula:C22H23N3O4
InChIKeys:InChIKey=AAKJLRGGTJKAMG-UHFFFAOYSA-N
Molecular Weight:393.44
Exact Mass:393.44
EC Number:1312995-182-4
UNII:J4T82NDH7E
DSSTox ID:DTXSID8046454
NCI Thesaurus Code:C65530
ATC Code:L01EB02|L01XE03|L - Antineoplastic and immunomodulating agents
HScode:29335990
Categories:
Characteristics-
PSA:
74.7
XLogP3:3.3
Density:1.24
Melting Point:159-160 °C
Boiling Point:553.6°C at 760 mmHg
Flash Point:288.6±30.1 °C
Refractive Index:1.615
Water Solubility:Very slightly soluble (hydrochloride salt - maximal solubility of approximately 0.4 mg/mL occurs at a pH of approximately 2)
Storage Conditions:Store at 25 deg C (77 deg F); excursions permitted to 15 - 30 deg C (59 - 86 deg F).
Vapor Pressure:7.06X10-11 mm Hg at 25 deg C (est)
Henrys Law Constant:Henry's Law constant = 1.03X10-17 atm-cu m/mol at 25 °C (est)
Dissociation Constants:pKa = 5.18 (benzylimine) (est)
Experimental Properties:MW: 429.90. MP: 228-230 °C. pKa (25 °C): 5.42. Solubility in water (pH approx 2): approximately 0.5 mg/mL. Slightly soluble in methanol. Practically insoluble in acetonitrile, acetone, ethyl acetate /Erlotinib hydrochloride/
Hazard IdentificationClassification of the substance or mixture
Carcinogenicity, Category 2
Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 4
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H351 Suspected of causing cancer
H413 May cause long lasting harmful effects to aquatic life
Precautionary statement(s) Prevention P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P273 Avoid release to the environment.
Response P318 IF exposed or concerned, get medical advice.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
vitamin
-
Location:
Room 2-502, Building 6, Luneng Tehran Garden Building, No.8 Changbin Road, Xiuying district, Haikou City, Hainan Province
-
Payment Terms:
TT against copy of documents,TT against B/L draft before shipment
-
Average lead Time:
25
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
Less than 5
-
Year of Establishment:
2023
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted 
India
Erlotinib white powder CAS 183321-74-6 best price Erlotinib
10 G Nov 14, 2023 Post an enquiry for this product
